Advertisement
UK markets open in 2 hours 51 minutes
  • NIKKEI 225

    41,365.53
    +174.85 (+0.42%)
     
  • HANG SENG

    17,766.63
    -249.31 (-1.38%)
     
  • CRUDE OIL

    81.65
    -0.26 (-0.32%)
     
  • GOLD FUTURES

    2,433.40
    +4.50 (+0.19%)
     
  • DOW

    40,211.72
    +210.82 (+0.53%)
     
  • Bitcoin GBP

    50,072.62
    +1,711.49 (+3.54%)
     
  • CMC Crypto 200

    1,348.02
    +79.07 (+6.23%)
     
  • NASDAQ Composite

    18,472.57
    +74.17 (+0.40%)
     
  • UK FTSE All Share

    4,490.19
    -32.56 (-0.72%)
     

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.